Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2019
At a glance
- Drugs Cenicriviroc (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Tobira Therapeutics
- 03 Sep 2018 Planned number of patients changed from 200 to 560.
- 22 Apr 2017 Planned End Date changed from 1 Dec 2019 to 31 Oct 2019.
- 22 Apr 2017 Planned primary completion date changed from 1 Dec 2019 to 21 Jul 2019.